Welcome to the European Consortium for Emergency Contraception (ECEC)
Founded in 2012, ECEC works to expand knowledge about and access to Emergency Contraception (EC) in Europe, and promotes the standardization of EC service delivery to ensure equitable access across the region. Since 2020, ECEC also works globally to advance access to EC.
EC is the only contraceptive method that can be used after sex, and it provides women with an additional opportunity to prevent a pregnancy.
Through this website, we hope to contribute to generating and sharing knowledge of EC in Europe and globally. Your contributions are essential to helping us achieve this goal, and we encourage you to share EC information about your country by writing to us at ecec [at] eeirh [dot] org.
Go directly to country-by-country information on EC access
Go directly to the online EC counseling tool (The EC wheel)
Latest News
Malta: EC pills to be included in National Formulary
January 2025. In December 2024, Maltese Health Authorities proposed including EC pills in the National Formulary, as part of the 2nd National Sexual Health Strategy 2025-2030. According to the Minister of Health, the strategy is based on comprehensive research conducted in 2022 and 2023, and is part of the national ongoing efforts to promote sexual…
Brasil: Use of EC pills among adolescent students
January 2025. A study by the Federal University of Minas Gerais (Belo Horizonte) aimed to estimate use of emergency contraception (EC) among Brazilian adolescent students, as well as the association of individual, family, and community factors with use. A cross-sectional study was carried out, including 38,779 Brazilian adolescent students, aged 13 to 17 years, participating…
UPA medicine for uterine fibroids remains available in a number of Latin American and CIS countries
December 2024. The marketing authorisation for Esmya was withdrawn in July from the European Economic Area and Belarus, Moldova, Serbia, Ukraine and the United Kingdom, at the request of the marketing-authorisation holder. (See announcement on the European’s Medicines Agency’s website here). The withdrawal was due to commercial reasons and there is no change in the safety…
